Figure 3 | Scientific Reports

Figure 3

From: Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

Figure 3

Mechanisms of action of emicizumab, rFVIIa, and aPCC DITMA. Overview of the mechanism of action in terms of major proteins and associated pathways linking “emicizumab plus rFVIIa” or “emicizumab plus aPCC” direct interactions to downstream characterized TMA effectors. Green lines indicate mechanisms triggered by “emicizumab plus aPCC” but not detected for “emicizumab plus rFVIIa” according to the models. Supplementary Fig. S1 and Supplementary Table S6 contain the sources of information found in the scientific literature supporting the predicted mechanisms. a activated, aPCC activated prothrombin complex concentrate, DITMA drug-induced TMA, F factor, rFVIIa recombinant activated factor VII, TMA thrombotic microangiopathy.

Back to article page